PPARG and inflammatory bowel disease: All the while, PPARγ ligands have been shown to halt clinical progression of IBD at different stages in mice models [1,15,16,17] and have even reached clinical trials in human IBD patients [6,18], but associated mechanisms have yet to be further studied.